Malcolm Spicer
Malcolm Spicer, Managing Editor – US

Latest From Malcolm Spicer
With Timetable In Hand And Icahn On Board, Bausch Health Looks To ‘Expedite Spin-Off’
Executives say Bausch + Lomb spin-out preparations will be completed by the end of Q3. When asked, they elaborated on Carl Icahn’s acquisition of 27.8m shares, for a 7.8% stake, and expansion of the firm’s board by two seats for Icahn’s representatives.
IFF Plus DuPont N&B Equals $11.2Bn Revenues
"Now it's up to us to look where can we accelerate our portfolio, in which areas and where can we grow the most and deliver good value for our customers,” says CEO Andreas Fibig.
‘Uniquely Positioned’ In Probiotics, IFF Emphasizes Ingredients For Women's, Cognitive, Skin Health
Jennifer Montgomery, IFF’s probiotics marketing manager for the Americas, responds to HBW Insight questions about the firm’s plans to deliver probiotics ingredients and technologies following the recent closing of its acquisition of DuPont Nutrition & Biosciences through a merger agreement.
China Q4 Sales Slip But Herbalife Has Record Year
Herbalife Q4 net sales up 15.6% to $1.4bn, a company record for the period, and full-year net sales increased 13.6% as its Asia Pacific, Europe-Middle East-Africa and North America regions reached annual net sales records. USANA reports 5.4% Q4 sales growth in China as full-year sales grew 7% to $1.135bn.
US Supplement Market Regulation: Depression Claim, Undisclosed Drug, COVID Tincture
A FDA warns 10 businesses they’re marketing unapproved and misbranded drugs by making claims for supplements to treat depression. Supplement also found with one of, if not the most common violations in the US supplement market: it contained an undisclosed ED drug.
Legislating CBD As Lawful Supplement Ingredient: A Threatening Precedent For US Industry?
Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act introduced in House isn’t supported by key Democrat and Republican leaders in both chambers partly because of regulatory precedent it proposes, says lobbyist NPA Steve Northrup.